Structure of gut microbiota and characteristics of fecal metabolites in patients with lung cancer

Abstract

ObjectiveThe gut micro-biome plays a pivotal role in the progression of lung cancer. However, the specific mechanisms by which the intestinal microbiota and its metabolites are involved in the lung cancer process remain unclear.MethodStool samples from 52 patients with lung cancer and 29 healthy control individuals were collected and subjected to 16S rRNA gene amplification sequencing and non-targeted gas/liquid chromatography-mass spectrometry metabolomics analysis. Then microbiota, metabolites and potential signaling pathways that may play an important role in the disease were filtered.ResultsFirmicutes, Clostridia, Bacteroidacea, Bacteroides, and Lachnospira showed a greater abundance in healthy controls. In contrast, the Ruminococcus gnavus(R.gnavus) was significantly upregulated in lung cancer patients. In this respect, the micro-biome of the squamous cell carcinoma(SCC)group demonstrated a relatively higher abundance of Proteobacteria, Gammaproteobacteria, Bacteroides,and Enterobacteriaceae, as well as higher abundances of Fusicatenibacter and Roseburia in adenocarcinoma(ADC) group. Metabolomic analysis showed significant alterations in fecal metabolites including including quinic acid, 3-hydroxybenzoic acid,1-methylhydantoin,3,4-dihydroxydrocinnamic acid and 3,4-dihydroxybenzeneacetic acid were significantly altered in lung cancer patients. Additionally, the R.gnavus and Fusicatenibacter of lung cancer were associated with multiple metabolite levels.ConclusionOur study provides essential guidance for a fundamental systematic and multilevel assessment of the contribution of gut micro-biome and their metabolites in lung cancer,which has great potential for understanding the pathogenesis of lung cancer and for better early prevention and targeted interventions.

Role of CD25 on resting Treg immune cell in Mediating the Effect of stearate biosynthesis microbiome pathway on lung adenocarcinoma

“…An increasing body of studies have shown that the GM may be involved in the development and progression of various types of cancer, such as breast cancer [27], gastrointestinal cancer [28] and lung cancer [29]. LUAD is the most common subtype of lung cancer.…”

The Causal Effect of Gut Microbiota and Plasma Metabolome on Lung Cancer and the Heterogeneity across Subtypes: A Mendelian Randomization Study

“…In recent years, several studies showed the important role of gut microbiota (GM) in LC pathogenesis and treatment. The results from Lu et al showed that Ruminococcus gnavus was significantly upregulated in LC patients, with Firmicutes, Clostridia, Bacteroidacea, Bacteroides, and Lachnospira being enriched in the healthy population [9]. Lee et al showed that bifidobacterium could improve sensitivity to immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC) patients [10].…”

Characteristics of gut microbiome in patients with pediatric solid tumor

“…Meanwhile, a growing body of research suggests an inseparable relationship between the occurrence and development of adult tumors and the gut microbiota. For instance, resident gut bacteria can influence patients' response to cancer immunotherapy ( 23 ), the gut microbiota possesses a unique ability to influence the tumor microenvironment as well as the metabolism of chemotherapy drugs or medications ( 24 ), the gut microbiota can modulate melanoma patients' response to PD-1 immunotherapy ( 25 ), the gut microbiota and its metabolites change with different stages of lung cancer development ( 26 ), the composition of the gut microbiota in patients diagnosed with colorectal cancer differs significantly from that of healthy individuals ( 27 ), based on specific changes in the gut microbiota, it is possible to screen for gut microbiota-targeted biomarkers and establish a diagnostic model, potentially serving as a non-invasive tool for distinguishing hepatocellular carcinoma ( 28 ), However, many aspects, including the mechanisms of onset, age of onset and characteristic features, differ between pediatric tumors and adult tumors. For instance, compared to adult tumors, childhood tumors generally exhibit a lower overall mutation burden ( 9 ).…”